Download PDF
Thromb Haemost 2005; 93(01): 153-159
DOI: 10.1160/TH04-04-0260
Cellular Proteolysis and Oncology
Schattauer GmbH

Haemostatic abnormalities and thrombotic disorders in malignant lymphoma

Tomohiro Sase
1   Second Department of Internal Medicine, Mie University School of Medicine, Tsu, Japan
,
Hideo Wada
2   Department of Laboratory Medicine, Mie University School of Medicine, Tsu, Japan
,
Motoko Yamaguchi
1   Second Department of Internal Medicine, Mie University School of Medicine, Tsu, Japan
,
Shoko Ogawa
1   Second Department of Internal Medicine, Mie University School of Medicine, Tsu, Japan
,
Yuko Kamikura
1   Second Department of Internal Medicine, Mie University School of Medicine, Tsu, Japan
,
Masakatsu Nishikawa
1   Second Department of Internal Medicine, Mie University School of Medicine, Tsu, Japan
,
Toshihiro Kaneko
3   Department of Safety Management, Mie University School of Medicine, Tsu, Japan
,
Yasunori Abe
4   Clinical Laboratories, Mie University Hospital, Tsu, Japan
,
Junji Nishioka
4   Clinical Laboratories, Mie University Hospital, Tsu, Japan
,
Tsutomu Nobori
2   Department of Laboratory Medicine, Mie University School of Medicine, Tsu, Japan
,
Hiroshi Shiku
1   Second Department of Internal Medicine, Mie University School of Medicine, Tsu, Japan
› Author Affiliations
Further Information

Publication History

Received 27 April 2004

Accepted after resubmission 19 October 2004

Publication Date:
14 December 2017 (online)

Also available at
   Permissions and Reprints

Summary

We examined haemostatic abnormalities and thrombotic disorders in 217 patients with malignant lymphoma. Plasma levels of fibrinogen and D-dimer were significantly higher in patients with malignant lymphoma than in healthy subjects.The incidence of severe complications, such as disseminated intravascular coagulation (DIC) and interstitial pneumonia (IP), differed with each clinical stage or histological type, but they occurred frequently in stage IV or natural killer (NK) cell lymphoma. Plasma levels of fibrinogen degradation products (FDP) and D-dimer, leukocyte tissue factor (TF) mRNA and plasma TF antigen were significantly higher in stage IV than in stage I, II or III. Plasma levels of FDP, D-dimer, and leukocyte TF mRNA in NK cell lymp homa were markedly higher than in other types of lymphoma. Immunohistochemical staining of NK cell lymphoma revealed that granulocyte macrophage colony-stimulating factor was positive in tumour cells, whereas von Willebrand factor and TF were positive in vascular endothelial cells of surrounding tissue. Our results suggested that patients with stage IV disease and NK cell lymphoma were in abnormal thrombotic and haemostatic state, and may frequently develop DIC and IP. One of the mechanisms of DIC and IP may involve elevated cytokine production by lymphoma cells, which can stimulate the expression of TF in blood cells or surrounding tissue.

Keywords

Malignant lymphoma - disseminated intravascular coagulation - interstitial pneumonia - thrombotic diseases - leukocyte tissue factor
 

  • References

  • 1 Donati MB. Cancer and thrombosis: from phlegmasia alba dolens to transgenic mice. Thromb Haemost 1995; 74: 278-81.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Pasquini E, Gianni L, Aitini E. et al Acute disseminated intravascular coagulation syndrome in cancer patients. Oncology 1995; 52: 505-8.
    CrossrefPubMedGoogle Scholar
  • 3 Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002; 87: 575-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Nakasaki T, Wada H, Mori Y. et al Decreased tissue factor and tissue-plasminogen activator antigen in relapsed acute promyelocytic leukemia. Am J Hematol 2000; 64: 145-50.
    CrossrefPubMedGoogle Scholar
  • 5 Goldschmidt N, Linetsky E, Shalom E. et al High incidence of thromboembolism in patients with central nervous system lymphoma. Cancer 2003; 98: 1239-42.
    CrossrefPubMedGoogle Scholar
  • 6 Sutherland DE, Weitz IC, Liebman HA. Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol 2003; 72: 43-52.
    CrossrefPubMedGoogle Scholar
  • 7 Lip GY, Chin BS, Blann AD. Cancer and the prothrombotic state. Lancet Oncology 2002; 3: 27-34.
    CrossrefPubMedGoogle Scholar
  • 8 Dasmahapatra KS, Cheung NK, Spillert C. et al An assessment of monocyte procoagulant activity in patients with solid tumors. J Surg Res 1987; 43: 158-63.
    CrossrefPubMedGoogle Scholar
  • 9 Callander NS, Varki N, Rao LV. Immunohistochemical identification of tissue factor in solid tumors. Cancer 1992; 70: 1194-201.
    CrossrefPubMedGoogle Scholar
  • 10 Wojtukiewicz MZ, Sierko E, Zacharski LR. et al Tissue factor dependent coagulation and impaired fibrinolysis in situ in gastric cancer. Semin Thromb Hemost 2003; 29: 291-300.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Nemerson Y, Bach R. Tissue factor revisited. Prog Haemostasis Thromb 1982; 6: 237-61.
    PubMedGoogle Scholar
  • 12 Contrino J, Hair G, Kreutzer DL. et al In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996; 2: 209-15.
    CrossrefPubMedGoogle Scholar
  • 13 Rickles FR. Relationship of blood clotting and tumor angiogenesis. Haemostasis 2001; 31: 16-20.
    PubMedGoogle Scholar
  • 14 Femandez PM, Patierno SR, Rickles FR. Tissue factor and fibrin in tumor angiogenesis. Semin Thromb Haemost 2004; 30: 31-44.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Hjortoe GM, Petersen LC, Albrektsen T. et al Tissue factor-factor VIIa specific upregulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood 2004; 103: 3029-37.
    CrossrefPubMedGoogle Scholar
  • 16 Shigemori C, Wada H, Matsumoto K. et al Tissue factor expression and metastatic potential of colorectal cancer. Thromb Haemost 1998; 80: 894-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Koyama T, Nishida K, Ohdama S. et al Determination of plasma tissue factor antigen and its clinical significance. Br J Haematol 1994; 87: 343-7.
    CrossrefPubMedGoogle Scholar
  • 18 Dorfleutner A, Ruf W. Regulation of tissue factor cytoplasmic domain phosphorylation by palmitoylation. Blood 2003; 102: 3998-4005.
    CrossrefPubMedGoogle Scholar
  • 19 Spek CA. Tissue factor: from just one of the coagulation factor to a major player in physiology. Blood Coagul Fibrinolysis 2004; 15: 3-10.
    CrossrefPubMedGoogle Scholar
  • 20 Wada H, Nakase T, Nakaya R. et al Elevated plasma tissue factor antigen level in patients with disseminated intravascular coagulation. Am J Hematol 1994; 45: 232-6.
    CrossrefPubMedGoogle Scholar
  • 21 Sase T, Wada H, Nishiokka J. et al Measurement of tissue factor messenger RNA levels in leukocytes from patients in hypercoagulable state caused by several underlying diseases. Thromb Haemost 2003; 89: 660-5.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Wada H, Ohiwa M, Kaneko T. et al Plasma level of tumor necrosis factor in disseminated intravascular coagulation. Am J Hematol 1991; 37: 147-51.
    CrossrefPubMedGoogle Scholar
  • 23 Wada H, Tamaki S, Tanigawa M. et al Plasma level of IL-1® in disseminated intravascular coagulation. Thromb Haemost 1991; 65: 364-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Franco RF, de Jonge E, Dekkers PE. et al The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: relationship with activation of coagulation. Blood 2000; 96: 554-9.
    PubMedGoogle Scholar
  • 25 McNally RJ, Roman E, Cartwright RA. Leukemias and lymphomas: time trends in the UK, 1984–93. Cancer Causes Control 1999; 10: 35-42.
    CrossrefPubMedGoogle Scholar
  • 26 Bick RL, Strauss JF, Frenkel EP. Thrombosis and hemorrhage in oncology patients. Hematol Oncol North Am 1996; 10: 875-907.
    PubMedGoogle Scholar
  • 27 Esmon CT. Role of coagulation inhibitors in inflammation. Thromb Haemost 2001; 86: 51-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Harris NL, Jaffe ES, Stein H. A revised European- American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-92.
    CrossrefPubMedGoogle Scholar
  • 29 Imamura T, Kaneda H, Nakamura S. New functions of neutrophils in the arthus reaction: Expression of tissue factor, the clotting initiator, and fibrinolysis by elastase. Lab Invest 2002; 82: 1287-95.
    CrossrefPubMedGoogle Scholar
  • 30 Mensink E, van de Locht, Schattenberg A. et al Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukemia patients using real time quantitative RT-PCR. Br J Hematol 1998; 102: 768-74.
    CrossrefPubMedGoogle Scholar
  • 31 Taylor Jr F, Toh CH, Hoots K. et al Towards definition clinical and laboratory criteria and a scoring system for disseminated intravascular coagulation. On behalf of the Scientific Subcommittee on disseminated intravascular coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Thromb Haemost 2001; 86: 1327-30.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Gouin-Thibault I, Achkar A, Samama MM. The thrombophilic state in cancer patients. Acta Haematol 2001; 106: 33-42.
    CrossrefPubMedGoogle Scholar
  • 33 Levi M. Cancer and DIC. Haemostasis 2001; 31: 47-8.
    PubMedGoogle Scholar
  • 34 Di Micco P, Romano M, Niglio A. et al Alteration of haemostasis in non-metastatic gastric cancer. Dig Liver Dis 2001; 33: 546-50.
    CrossrefPubMedGoogle Scholar
  • 35 Palumbo JS, Kombrinck KW, Drew AF. et al Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000; 15: 3302-9.
    PubMedGoogle Scholar
  • 36 Dirix LY, Salgado R, Weytjens R. et al Plasma fibrin D-dimer levels correlate with tumor volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer 2002; 86: 389-95.
    CrossrefPubMedGoogle Scholar
  • 37 Kohli M, Fink LM, Spencer HJ. et al Advanced prostate cancer activates coagulation: a controlled study of activation makers of coagulation in ambulatory patients with localized and advanced prostate cancer. Blood Coagul Fibrinolysis 2002; 13: 1-5.
    CrossrefPubMedGoogle Scholar
  • 38 Semeraro N, Montemurro P, Giordano P. et al Increased mononuclear cell tissue factor and type-2 plasminogen activator inhibitor and reduced plasma fibrinolytic capacity in children with lymphoma. Thromb Haemost 1994; 72: 54-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 39 Cushman M, Folsom AR, Heckbert SR. Fibrin fragment D-dimer and the risk of future venous thrombosis. Blood 2003; 101: 1243-8.
    CrossrefPubMedGoogle Scholar
  • 40 Sallah S, Wan JY, Sigounas G. Disseminated intravascular coagulation in solid tumors: clinical and pathologic study. Thromb Haemost 2001; 86: 828-33.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Wada H, Nagano T, Tomeoku M. et al Coagulation and fibrinolytic activities in the leukemic cell lysates. Thromb Res 1982; 30: 315-22.
    PubMedGoogle Scholar
  • 42 Nakasaki T, Wada H, Watanabe R. et al Elevated tissue factor levels in leukemic cell homogenate. Clin Appl Thromb Haemost 2000; 6: 14-7.
    CrossrefPubMedGoogle Scholar
  • 43 Nakasaki T, Wada H, Shigemori C. et al Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer. Am J Hematol 2002; 69: 247-54.
    CrossrefPubMedGoogle Scholar
  • 44 Salgado A, Boveda J, Monasterio J. et al Inflammatory mediators and their influence on haemostasis. Haemostasis 1994; 24: 132-8.
    PubMedGoogle Scholar
  • 45 Gregory SA, Morrissey JH, Edgington TS. Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin. Mol Cell Biol 1989; 9: 2752-5.
    CrossrefPubMedGoogle Scholar
  • 46 Imokawa S, Sato A, Hayakawa H. et al Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis. Am J Respir Crit Care Med 1997; 156: 631-6.
    CrossrefPubMedGoogle Scholar
  • 47 Gunther A, Mosavi P, Ruppert C. et al Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease. Thromb Haemost 2000; 83: 853-60.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 48 Idell S, Gonzalez K, Bradford H. et al Procoagulant activity in bronchoalveolar lavage in the adult respiratory distress syndrome. Contribution of tissue factor associated with factor VII. Am Rev Respir 1987; 136: 1466-74.
    PubMedGoogle Scholar
  • 49 Kotani I, Sato A, Takada A. Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis. Thromb Res 1995; 77: 494-504.
    PubMedGoogle Scholar
  • 50 Weitz IC, Israel VK, Waisman JR. et al Chemotherapy- induced activation of haemostasis: effect of a low molecular weight heparin (daiteparin sodium) on plasma makers of haemostatic activation. Thromb Haemost 2002; 88: 213-20.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 51 Berkani K, Bayle JY, Perol M. et al "Spontaneous" resolution of two severe methotrexate-induced pneumonias. Rev Pneumol Clin 2003; 59: 301-5.
    PubMedGoogle Scholar
  • 52 Jullien V, Perrin C, Peyrade F. et al A case of acute respiratory failure related to rituximab therapy. Rev Mal Respir 2004; 21: 407-10.
    CrossrefPubMedGoogle Scholar
  • 53 Nitsu N, Iki S, Muroi K. et al Interstitial pneumonia in patients receiving granulocyte colony-stimulating factor during chemotherapy: survey in Japan 1991–96. Br J Cancer 1997; 76: 1661-6.
    CrossrefPubMedGoogle Scholar